Each film coated tablet of KLARI tab® 500 contains:

• Clarithromycin  500  mg.

Each film coated tablet of KLARI tab® 250 contains:

• Clarithromycin  250  mg.

KLARI tab® is used to treat the below listed infections caused by the susceptible micro-organisms:-

• Upper respiratory tract infections: pharyngitis, tonsilitis, sinusitis, acute otitis media.
• Lower respiratory tract infections: Acute and chronic bronchitis, pneumonia.
• Soft tissue and dermal infections: pyoderma, impetigo, cellulitis, folliculitis, legionella and chlamydia infection, ecthyma, erysipelas, lymphangitis and infected dermal lesions, also it is used for the treatment of leprosy and prophylaxis and treatment of opportunistic Mycobacterial infection.
• KLARI tab® in the presence of acid suppression is indicated for the eradication of Helicobacter pylori in pateints with peptic ulcers and it has been tried in protozoal infections including toxoplasmosis.

• Hypersensitivity to Clarithromycin or any macrolide antibotics.
• Concomitant administration of Clarithromycin with Cisapride, Pimozide or Terfenadine is contraindicated because it results in cardiac arrhythmias.

• KLARI tab® increased efficacy of the following drugs, which are metabolized by the cytochrome P450 system: Digoxin, Warfarin, Ergot  Alkaloid, Triazolam and Cyclosporins.
• KLARI tab® toxicity is increased in patients receiving clarithromycin and rifabutin.
• KLARI tab® increases plasma concentrations of Carbamazepine and Theophylline following concomitant use with single doses of Clarithromycin.

• KLARI tab® should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

• Clarithromycin is well tolerated, gastrointestinal adverse effects with oral clarithromycin therapy are lower than that of conventional macrolides  Such as; (Nausea, vomiting, dyspepsia, diarrhoea, abdominal discomfort, and abnormal taste may occur).
• Headache, pseudomembranous colitis, have been reported.
• Allergic reactions ranging from mild urticaria and mild skin eruptions to rare cases of anaphylaxis and Steven - Johnsons syndrome, have occured.
• Hepatic dysfunction may be severe and is usually reversible.
• In very rare instances, hepatic failure has been reported and generally has been associated with serious underlying disease, and /or concomitant medications.
• Rarely, erythromycin and clarithromycin have been associated with ventricular arrhythmia. 

1) Adult :

For acute sinusitis:

• 250mg/ 12 hours for 14 days.

For pharyngitis and tonsillitis:

• 250mg/ 12 hours for 10 days.

For eradicate of H.pylori:

• 500mg two times daily for 14 days in combination with an oral anti ulcer

2) Children: (younger than 12 years) :

• 7.5mg/ kg body weight every 12 hours for 5-10 days.

* Dose adjustment is necessary in patients with severe renal impairment 
  (creatinine clearance < 30 ml/min), the total dosage should be reduced by 
  half e.g. 250 mg once daily or 250 mg twice daily in more severe infection.

Over dose:-

• Reports indicate that the overdose of Clarithromycin can be expected to produce gastrointestinal symptoms.
• Allergic reaction produced should be treated by gastric lavage and supportive measures.

• In presence of severe renal impairment with or without co-existing  impairment, decreased dosing intervals may be appropriate. 
• The possibility  of superinfection should be kept in mind during therapy. If superinfections occur, the drug should be discontinued and appropriate therapy instituted. 
• The safety and effectiveness of Clarithromycin in children under 6 months of age have not been established.

• KLARI tab® 500 Film coated tablets (blister of 7 tablets, Pack of two blisters).
• KLARI tab® 250 Film coated tablets (blister of 7 tablets, Pack of two blisters).

• Store below 30 OC.